Business
Enzolytics, Inc. Engages PCAOB Auditor for December 31, 2020 Year End Audit
Enzolytics, Inc. Engages PCAOB Auditor for December 31, 2020 Year End Audit.
About this update from Enzolytics Inc.
[{"type":"text","content":"COLLEGE STATION, TX / ACCESSWIRE / January 11, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today, announced it has accepted a proposal from a Houston based PCAOB Audit firm to Audit the Company's year-end financial statements, subject to the receipt and acceptance of the engagement letter. The proposal covers the 2019 and 2020 calendar years for filing with the OTC Markets.The Company's current accounting firm, Mallet & Barnes, will continue working with the Company to file the year-end financials for 2020 under the Pink Basic Disclosure Guidelines to ensure the continued timely filing of the required financial information during the initial audit of the Company. Future quarterly filings will be reviewed by the auditing firm.On January 8, 2021, Enzolytics received comments from the OTC Markets Compliance Department referencing the September 30, 2019 filings and has made the edits and suggested changes, correcting the filings today.In addition, the first tranche of additional funding has been received and with the engagement of the PCAOB auditor, the third tranche from the outside investors along with the first tranche from management should be received this week which will bring the total new funding since September 15, 2020 to $1,300,000.00."We are excited about working with our new auditors and achieving fully reporting status. The Company has been focusing on several fronts on which we have made considerable progress. Administratively, we have achieved our goal of bringing our filings current and expect the yield sign to be lifted eminently. We have engaged the Auditor to issue an audited statement in order to achieve our goal of fully reporting by April, if not sooner. One of our top priorities is finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria. We have received proposals from FDA approved manufacturers to produce the quantities necessary for such certification and those are under review. Our lab at Texas A & M University meets our exact needs for completing development of additional monoclonal antibodies for treatment of the HIV and SARS-CoV-2 viruses," stated Charles Cotropia, CEO.About Enzolytics, Inc.;Enzolytics, Inc. is a drug development company committed to the commercialization of its pr...